立体定向放射外科治疗大型颅内脑膜瘤的系统综述
本系统综述纳入496例患者共452个最大径≥2.5 cm(体积≥8.1 cm³)的大型颅内脑膜瘤,评估立体定向放射外科(SRS)作为初治或辅助治疗的有效性与安全性。随访中位54个月,影像学肿瘤控制率为84%–100%,放射性毒性发生率为23%,非单次伽玛刀治疗者临床症状改善的可能性约为单次治疗者的2倍。
要点
- SRS对大型颅内脑膜瘤的影像学肿瘤控制良好,末次随访控制率84%–100%。
- 放射性毒性总体发生率为23%,以颅神经病变(5.5%)和瘤周水肿(5.3%)最常见。
- 非单次伽玛刀治疗者临床症状改善的可能性约为单次治疗的2倍(OR 2.47)。
核心结论
- SRS作为大型颅内脑膜瘤的初治或辅助治疗安全有效。
- 非单次伽玛刀治疗者临床症状改善的可能性约为单次伽玛刀治疗的2倍(OR 2.47;95%CI 1.38–4.44;P=0.002)。
- 仍需进一步前瞻性研究验证上述结果。
研究设计与样本
- 系统综述,纳入496例患者共452个最大径≥2.5 cm(肿瘤体积≥8.1 cm³)的大型颅内脑膜瘤。
- 患者中位年龄60岁(48–65岁),女性350例(69.3%)、男性146例(30.6%)。
- 诊断时中位肿瘤体积16.7 cm³(10–53.3 cm³),SRS后中位随访54个月(18–90个月)。
- 87.8%的患者接受单次伽玛刀放射外科治疗,其余12.1%接受非单次伽玛刀治疗。
主要发现
- 452个大型颅内脑膜瘤中,SRS后45.1%临床症状改善、15.7%恶化。
- 末次随访(2–7.5年)影像学肿瘤控制率为84%–100%。
- 肿瘤多位于颅底(77.2%),仅14.6%位于幕上。
- 放射性毒性发生于23%的患者,最常见为颅神经病变(5.5%)和瘤周水肿(5.3%)。
关键数值与推荐
- 大型颅内脑膜瘤定义为最大径≥2.5 cm,对应肿瘤体积≥8.1 cm³。
- 非单次与单次伽玛刀治疗相比,临床症状改善的OR为2.47(95%CI 1.38–4.44;P=0.002)。
- 影像学肿瘤控制率在末次随访(2–7.5年)为84%–100%。
临床怎么用
- 对最大径≥2.5 cm的大型颅内脑膜瘤,SRS可作为初治或辅助治疗的选择。
- 治疗前应评估颅神经功能与瘤周水肿风险,治疗后需随访影像学与临床症状。
- 对适合分次治疗者,非单次伽玛刀方案可能更有利于症状改善。
局限性
- 本文为系统综述,纳入研究以回顾性资料为主,证据等级有限。
- 随访时间与肿瘤控制评估时点不一(2–7.5年),异质性可能影响结论。
- 原文指出仍需前瞻性研究验证结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gross total resection of large intracranial meningiomas (LIMs) can be challenging and cause significant morbidity and mortality. The aim of this systematic review is to determine the clinical effectiveness and safety of stereotactic radiosurgery (SRS) either as primary or adjuvant therapy for LIMs with tumors ≥2.5 cm in maximum dimension (tumor volume ≥8.1 cm3). A total of 452 tumors in 496 patients (350 female [69.3%] and 146 male [30.6%]) with median age 60 years (48-65 years) were included. The median tumor volume at the time of diagnosis was 16.7 cm3 (10-53.3 cm3). The tumors typically were located in the skull base (77.2%), whereas only 14.6% were in the supratentorial space. The median follow-up after SRS was 54 months (18-90 months). In total, 87.8% of patients were treated with single-session (SS) Gamma Knife radiosurgery (GKS), whereas the remaining 12.1% patients received non-SS GKS. Of 452 LIMs assessed for clinical response, 45.1% showed improvement and 15.7% deteriorated after SRS. Radiographic tumor control at last follow-up (2-7.5 years) ranged from 84% to 100%. Overall, radiation-induced toxicity occurred in 23% of patients, with the most common adverse effect being cranial nerve neuropathy (5.5%) and peritumoral edema (5.3%). Subgroup analysis revealed that there is 2-fold greater likelihood of improvement in clinical symptoms in patients with non-SS GKS than SS GKS (odds ratio 2.47; 95% confidence interval 1.38-4.44; P = 0.002). SRS is safe and effective in the treatment of LIMs as primary or adjuvant treatment. Further prospective studies are required to validate our results.
引用
- Fatima N, Meola A, Pollom E, et al. Stereotactic Radiosurgery in Large Intracranial Meningiomas: A Systematic Review. World Neurosurg. 2019. PMID: 31226450. doi:10.1016/j.wneu.2019.06.064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。